Articolul precedent |
Articolul urmator |
423 5 |
Ultima descărcare din IBN: 2023-11-16 22:42 |
SM ISO690:2012 GROSU, Stanislav, AFTENE, Vadim. Insomnia cronică asociată cu abuzul de substanțe psihoactive noi. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 357. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 357-357 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Chronic insomnia is a common disease in the general population and in people with drug addiction and abuse. Mental disorders as a result of the abuse of new psychoactive substances (designer drugs) are directly associated with sleep disorders, mainly chronic insomnia and parasomnias. Objective of the study. Short narrative presentation on the topic of the relation of chronic insomnia and other sleep disorders associated to these drugs, namely synthetic cathinones, synthetic cannabinoids, piperazines, phenethylamines and new benzodiazepines and opioids. Material and Methods. PubMed, WoS and JSTAGE databases were searched according to the keywords and associations ‘chronic insomnia’ ‘new psychoactive substances’ ‘sleep disorders’ ‘designer drugs and sleep’. More than 300 abstracts of thematic papers were identified, and after the appropriate selection of informational content, 44 papers with full-text access were selected, including systematic reviews. Results. The proportion of individuals aged 16-65 who have used new psychoactive substances at least once in their lives varies between 2.4-6.8% in different countries of the world, and people aged 18-50 who have used designer drugs in the last month in Europe represents 1.8-3.3% (EMCDDA). Sleep disorders are the most common comorbidity identified in abuse and dependence of new psychoactive substances (60-85%), with chronic insomnia and parasomnias having the highest incidence. Also, the association of insomnia and affective disorders such as anxiety disorders, depression or episodes of exogenous psychosis and convulsions is highlightened in the literature. Conclusion. Chronic insomnia is the most common comorbidity associated with the consumption of new psychoactive substances. The risk of repeated administration of these drugs is also high for the development or exacerbation of premorbid mental states, along with multisystemic somatic impairment. |
||||||
Cuvinte-cheie chronic insomnia, new psychoactive substances, designer drugs, insomnie cronică, substanțe psihoactive noi, designer drugs |
||||||
|